Peter Neumann

Variation in US Commercial Health Plan Coverage Restrictions for Cell and Gene Therapies This Viewpoint examines variations in US commercial health plan coverage restrictions for cell and gene therapies.

Our new research letter in JAMA, led by James Chambers, highlights variation in how US commercial health plans impose coverage requirements for cell & #gene therapies.

jamanetwork.com/journals/jam... @tuftscevr.bsky.social

Pleased to join this distinguished group of authors in paying tribute to the great John Iglehart, founding editor of Health Affairs, who passed away in June.

tinyurl.com/47rnt9yf @tuftscevr.bsky.social @healthaffairs.bsky.social

Characterizing financial risk from out‐of‐pocket expenditures across dementia stages INTRODUCTION Older adults with dementia incur considerable out-of-pocket (OOP) health care expenses, but it is unclear how their financial burden differs by dementia stage. METHODS We identified 2...

New Tufts-CEVR research led by @pattysynnott.bsky.social highlights:
- high out-of-pocket costs of older adults living with dementia
- financial risks increase in advanced dementia states.

alz-journals.onlinelibrary.wiley.com/doi/10.1002/... #Alzheimers #dementia

In this just published paper in Value in Health led by Feng Xie and colleagues, we reviewed the published cost-effectiveness evidence for the 15 drugs selected for IPAY 2027 Medicare negotiations.

@djvanness.bsky.social @ankurfactorial.bsky.social
www.valueinhealthjournal.com/article/S109...

@icer-review.bsky.social @tuftscevr.bsky.social @peterneumann11.bsky.social @pattysynnott.bsky.social

Welcome, Dave!

CEVR is thrilled to welcome David Strutton, PhD, as a Senior Fellow! Dr. Strutton brings 30+ years of global leadership in health policy, biopharma, and HTA. His expertise in real-world evidence and access strategy will be a tremendous asset.

Read more at: tinyurl.com/3bz9te3p

Excited to announce that David Strutton, Ph.D., a distinguished leader in healthcare policy, biopharmaceuticals, #vaccines, and #healtheconomics is joining Tufts-CEVR as a Senior Fellow.

Announcement here: cevr.tuftsmedicalcenter.org/news/david-s... @tuftscevr.bsky.social

VUMC researchers host international fellows for economic evaluation, decision science training Vanderbilt recently hosted 11 international fellows to provide training to help them address public health issues in their home countries.

Great application of our CEA Registry at the #Vanderbilt Center for Health Economic Modeling: 11 international fellows from #LMICs used the Registry to conduct CEAs of public health interventions.

Read more at: tinyurl.com/88varaue

@peterneumann11.bsky.social #ISPOR

Value assessment for health services and procedures: a call to action in a new political climate

New in JCER: CEVR’s Meng Li and @peterneumann11.bsky.social call for more value assessment of health services/procedures. These interventions are ~70% of health care spending but are often implemented without robust evidence and, unlike drugs, can cost more over time.

Read: tinyurl.com/ycxrppby

Health Economics and Outcomes Research (HEOR) Certificate Program - Tufts CTSI Overview The Tufts University Graduate School of Biomedical Sciences (GSBS) Clinical and Translational Science (CTS) Graduate Program is delighted to offer an accredited Certificate Program in Health ...

Two weeks left to apply: Earn your #HEOR Certificate online from @tufts.edu with globally-recognized faculty like @peterneumann11.bsky.social, @dano-hta.bsky.social, James Chambers, and more from CEVR. Apply today!

Deadline is Aug. 1.

tinyurl.com/pr6drkhf

#RWE #pharma

Larry Mose, MSc is today’s #CEARegistry Summer fellow. Larry earned his MSc from @york.ac.uk and hopes to work in the field of #HEOR.

Our thanks to the @moorefound.bsky.social ‬for funding the CEA Registry Fellowship program!‬‬

1/ How closely do health plans’ drug #utilizationmanagement (UM) policies align with #clinicalguidelines? CEVR and NPC examined policies for 389 drug-indication pairs from 18 commercial insurers. Here’s a thread on what we found:

Some personal reflections about John Iglehart (1939-1975), Founding Editor of Health Affairs.

cevr.tuftsmedicalcenter.org/news/in-reme... @tuftscevr.bsky.social

New Tufts-CEVR paper in the J of Alzheimer's Disease, led by Paige Lin, provides updated health utility estimates for persons with AD and their caregivers across disease stages and settings.

journals.sagepub.com/doi/10.1177/... @tuftscevr.bsky.social @pattysynnott.bsky.social #Alzheimers

Pleased to introduce the 2025 cohort of the Tufts-CEVR CEA Registry Summer Fellowship Program, supported by the Gordon and Betty Moore Foundation.

cevr.tuftsmedicalcenter.org/news/2025-ce... @tuftscevr.bsky.social @pattysynnott.bsky.social

CEVR is thrilled to introduce the 2025 cohort of the Tufts-CEVR CEA Registry Summer Fellowship Program, which is supported by the @moorefound.bsky.social. Stay tuned over the next two months for featured posts about each fellow!

More details at: cevr.tuftsmedicalcenter.org/news/2025-ce...

Congrats, Mel!

New in Value in Health: three former CEA Registry Summer Fellows (Xujun Gu, Hanwen Zhang, and Divya Patil) and U of Maryland's Julia Slejko used the CEA Registry to explore the utility of AI-assisted data extraction.

Read at tinyurl.com/37mh5n6m

ISPOR and CEVR are partnering to offer free premium access to the CEA Registry for students + academic/government researchers in LMICs.

Unlock data from 14,000+ cost-effectiveness studies, advanced tools, and more.

More at: tinyurl.com/5y3vpsz3

#HEOR #GlobalHealth #ISPOR

We're excited to announce Tufts-CEVR's new partnership with ISPOR to provide free, premium access to the CEA Registry for ISPOR members who are students or researchers in LMICs.

More detail here: cevr.tuftsmedicalcenter.org/news/cevr-is...

@djvanness.bsky.social @tuftscevr.bsky.social

With @tuftscevr.bsky.social colleagues #ISPORAnnual in Montreal.

Thanks to all my wonderful Tufts-CEVR colleagues for putting on another great annual meeting! Proud to work with you!

@dano-hta.bsky.social @brianreid.bsky.social @tuftscevr.bsky.social @mollytoba.bsky.social

Congrats!

Can Prevention Save Money? This JAMA Forum discusses some key considerations for addressing the question of whether and when prevention interventions are worth the cost.

This right question about prevention: not whether it saves money, but whether it is worth the cost.

tinyurl.com/3ezrrvm4 @tuftscevr.bsky.social #health #prevention

Reports about the death of QALYs is greatly exaggerated. My new blog post:

cevr.tuftsmedicalcenter.org/news/the-dea... @dano-hta.bsky.social @tuftscevr.bsky.social #HEOR #QALYs

Medicare coverage policy for new technologies may change substantially in the new Administration.

Our analysis here: tinyurl.com/yuj67caf @healthaffairs.bsky.social @tuftscevr.bsky.social @kathrynp-phd.bsky.social

How will Trump admin reform Medicare’s #CED program? Return to the #MCIT paradigm, default enrollment in #Medicare Advantage, etc?

In HA Forefront: Tunis, Hatfield, Patel, & @peterneumann11.bsky.social argue against removing CED + for efficient data collection.

Read: tinyurl.com/yuj67caf

Our new piece in @healthaffairs.bsky.social on #Medicare coverage of new technologies in this new era.

Key points:
- CMS shouldn't eliminate coverage w/ evid development
- instead, efforts should focus on more efficient post-market evidence generation.

tinyurl.com/yu4rzkr2 @tuftscevr.bsky.social

New study by my @tuftscevr.bsky.social colleague, Yolanda Zhu and colleagues.

The #IRA #Medicare Part D benefit redesign may significantly lower OOP drug spending for beneficiaries with #dementia and comorbidities.

tinyurl.com/5n8uxam3 #IRA #drugs